TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’s Entyvio, a CAM inhibitor, Janssen’s Stelara, an IL-12/23 inhibitor, and AbbVie’s Skyrizi, an IL-23 inhibitor) are mostly used as later-line therapies, following anti-TNF failure. These agents have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. Meanwhile, significant need remains, especially in the treatment of patients with CD refractory to available therapies and those with fistulizing disease.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 32 European gastroenterologists fielded in January 2023
Key companies: AbbVie, Janssen, Takeda, UCB, Celltrion Healthcare
Key drugs: Remicade, infliximab biosimilar (IV), Entyvio, Stelara, Skyrizi, Humira, adalimumab biosimilar, Remsima SC